Aducanumab

Biogen Gets FDA Nod For Controversial Alzheimer's Drug; First Treatment Approval For The Disease In 18 Years

Biogen Shares Jump After FDA Delays Aducanumab Decision By 3 Months

Analysts Predict Volatility In Biogen Shares Until March 2021

Biogen Shares Jump After FDA Delays Aducanumab Decision By 3 Months

Analysts Predict Volatility In Biogen Shares Until March 2021

Biogen's Aducanumab Fails To Win FDA Panel Backing

Biogen Surges Higher On Favorable FDA Briefing Doc For Alzheimer's Candidate

Biogen's Aducanumab Fails To Win FDA Panel Backing

Biogen Surges Higher On Favorable FDA Briefing Doc For Alzheimer's Candidate

Biogen Soars As FDA Accepts Alzheimer's Drug For Review In 'Next Stage Of Aducanumab Saga'

Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay

Aducanumab Recent News

Biogen Delays Regulatory Filing For Approval Of Alzheimer's Drug, Shares Slump

Biogen Inc (NASDAQ: BIIB) shares were under pressure Wednesday following the release of the biotech's first-quarter report, including the statement that Biogen's BLA filing for its Alzheimer's drug will be delayed.

Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says

Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation

Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response

Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade

Cramer Makes The Case Why Biogen's Stock Could Double In Value

Biogen Analysts Debate About-Face On Aducanumab: 'Path To Market An Uphill Battle'

Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'

Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study

After Biogen's Alzheimer's Update, Wall Street Reacts

Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs

Biogen's Best-In-Class R&D Earn Makes It A Buy

Biogen's Core Business Impresses While Potential Alzheimer's Catalyst Looms

19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug

Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail

Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects

Experts React To Concerning Alzheimer's News From Lilly

Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug

Wall Street Mixed On Biogen Before Earnings

Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence…Even More Speculative Than Before'

Disappointing Drug News Sends Biogen And XOMA Shares Down

RBC Says Biogen Can Move 10% After BIIB-037 Data Is Revealed